ReviewFrontiers in pharmacology2025
Efficacy of Xuebijing injection on pulmonary ventilation improvement in acute pancreatitis: a systematic review and meta-analysis.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review and network meta-analysis of single nucleotide polymorphisms associated with oral submucous fibrosis risk.Medicine · 2026Pooled it
- Comparative efficacy and safety of Xuebijing injection as adjuvant therapy in sepsis-associated acute kidney injury: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Efficacy, immunogenicity, and safety of pneumococcal conjugate vaccine in children: a systematic review and meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Integrated in vivo and in vitro experiments with multi-omics analysis reveal SPP1 drives pancreatic cancer progression.BMC cancer · 2026Article
- Nanotherapy for acute pancreatitis: a systematic review of experimental strategies and mechanisms of action.Discover nano · 2026Review
- Epidermal growth factor receptor regulates Beclin-1 in hyperoxic acute lung injury.BMJ open respiratory research · 2026Article
- Modeling and dynamical analysis of the impact of alcohol consumption on tuberculosis transmission with optimal control strategies.Scientific reports · 2025Article
- The Emerging Role of the Cancerous Inhibitor of Protein Phosphatase 2A in Pulmonary Diseases.Medicina (Kaunas, Lithuania) · 2025Review
- Enhancing Radiotherapy for Hypoxic Tumors: Integrative Strategies Using Bacteria and Nanoparticles.IET nanobiotechnology · 2025Review
- Cost analysis and cost-effectiveness of traditional Chinese medicine in lung cancer: a scoping review.Frontiers in public health · 2025Article
- Vitamin D deficiency and asthma morbidity in school-age children: a single-center cohort study.Frontiers in public health · 2025Article
- Xuebijing injection in the treatment of COVID-19: An update on clinical studies, potentially active metabolites and mechanisms.Frontiers in pharmacology · 2025Review
- Weighted gene co-expression network analysis identifies functional modules related to bovine respiratory disease.PloS one · 2025Article
- The mechanism of short-chain fatty acid in hypertriglyceridemic pancreatitis.Frontiers in microbiology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Xuebijing injection (XBJI), as a Chinese patent medicine injection, consists of five botanical drugs for anti-inflammatory treatment. Acute pancreatitis (AP) is induced by localized inflammation, potentially resulting in multiple organ dysfunction syndromes, specifically including acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Recent studies suggest that XBJI effective in alleviating potentially easing ALI and ARDS. Objective: We illustrated the efficacy and safety of XBJI for pulmonary function of AP by conducting a systematic literature review and meta-analysis. Methods: We conducted searches across eight databases, including PubMed, Embase, and the Cochrane Library, up to September 2024. Two independent investigators screened and selected the literature based on predefined inclusion and exclusion criteria, followed by data extraction. The quality of the selected studies was assessed using the Cochrane Collaboration's Risk of Bias 2.0 tool. The data were then qualitatively analyzed and synthesized by using Review Manager software, in accordance with the PRISMA guidelines and the Cochrane Handbook. Conclusion: This study showed that using conventional therapy combined with XBJI might increase the oxygenation index, lower the respiratory rate, and improve APACHE II scores and inflammatory biomarkers. However, there is a high risk of bias and the quality of the included studies is low. More well-designed, large-sample, and high-quality trials are needed to be conducted in multiple centers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.